Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Alvocidib + Decitabine + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Alvocidib||flavopiridol|HMR 1275|L-868275|DSP-2033||CDK Inhibitor (Pan) 4 CDK1 Inhibitor 13 CDK2 Inhibitor 22 CDK4 Inhibitor 14 CDK6 Inhibitor 4 CDK7 Inhibitor 14 CDK9 Inhibitor 19||Alvocidib (flavopiridol) is an inhibitor of CDK1, CDK2, CDK4, CDK6, CDK7, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 12165651, PMID: 8674031, PMID: 24470357).|
|Decitabine||Dacogen||5-aza-2-deoxycytidine||DNMT inhibitor (Pan) 5||Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119||BCL2 inhibitor 23||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04493099||Phase Ib/II||Alvocidib + Decitabine + Venetoclax||Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML||Withdrawn||USA||0|